ESC 365 - Impact of P-glycoprotein and/or CYP3A4-interacting drugs on the risk-benefit profile of NOACs in patients with atrial fibrillation: a meta-analysis

EHRA Premium Access

Impact of P-glycoprotein and/or CYP3A4-interacting drugs on the risk-benefit profile of NOACs in patients with atrial fibrillation: a meta-analysis

Session: Moderated ePosters - How to optimise stroke prevention in atrial fibrillation

Topic: Oral Anticoagulation

Speaker: Mr M. Grymonprez (Gent, BE)

Event: EHRA 2022

Congress Presentation

Add to my library

About the speaker

Mr Maxim Grymonprez

University Hospital Ghent, Gent (Belgium)

0 follower

3 more presentations in this session

One-year results from the FLXibility post-approval study: final real-world clinical outcomes with a next-generation left atrial appendage closure device

Speaker: Professor T. Betts (Oxford, GB)

Prevalence and outcomes of hypoattenuation defects and appendage patency on computed tomography after left atrial appendage closure

Speaker: Professor H. Cochet (Bordeaux, FR)

Single versus dual antiplatelet therapy following transcatheter left atrial appendage closure

Speaker: Doctor A. Sabbag (Ramat Gan, IL)

Access the full session

Moderated ePosters - How to optimise stroke prevention in atrial fibrillation

Speakers: Mr M. Grymonprez, Professor T. Betts, Professor H. Cochet, Doctor A. Sabbag

About the event

EHRA 2022

3 April - 5 April 2022

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources